Biogenetics Research
Past the peritoneum. Into the tumour. Past platinum resistance.
We build targeted nanoparticle carriers for high-grade serous ovarian cancer — and we run the quantitative image analysis that turns tissue into evidence, for our own pipeline and for yours.
96.4 nm
Z-average diameter
0.087
Polydispersity index
−24.3 mV
Zeta potential
91.2 %
Encapsulation efficiency
We run a drug pipeline and a services lab out of the same building — on purpose.
The image analysis methods we sell were built to answer our own questions about tumour penetration and dose response. Clients get tooling that has already survived contact with a live pre-clinical programme.
Track A — Internal pipeline
Nanomedicine for ovarian cancer
High-grade serous ovarian cancer relapses in most patients, and platinum resistance is what usually kills them. We design carriers that reach disseminated peritoneal disease, stay there, and deliver two agents at once.
- Folate receptor alpha as the primary targeting vector
- Intraperitoneal administration with retention-tuned carriers
- Co-delivery of cytotoxic payload plus a resistance-reversal nucleic acid
Track B — Client services
AI-enabled research services
Quantitative digital pathology and AI image analysis for pharma, biotech and academic groups — from single chromogenic IHC through to high-plex immunofluorescence, at discovery scale or to a regulatory standard.
- Cell-by-cell quantification of nuclear, membrane and cytoplasmic markers
- Custom segmentation and classification models, verified then locked
- Short-term fee-for-service or longer-term embedded FTE scientists
What we do for clients
Tissue images in. Defensible numbers out.
Five service lines, matched to research phase and to how much of the work you want to keep in-house.
Research phase
Discovery & pre-clinical
Target validation, compound efficacy in diseased tissue, and high-throughput screening across large image sets.
Read more →Research phase
Clinical
Consistent quantification across trial batches, with pathologist input on annotation and region selection.
Read more →Research phase
GCP-compliant studies
Image analysis performed to SOPs inside a documented quality management framework, with a full audit trail.
Read more →Capability
AI image analysis
Bespoke nuclear, cell and tissue segmentation models for heterogeneous or awkwardly stained material.
Read more →Capability
Flexible resourcing
Per-study pricing when the work is bounded, or dedicated analysts embedded with your team when it isn't.
Read more →Overview
Therapeutic areas
Gynaecological and immuno-oncology first, plus fibrosis, CNS, dermatology, cardiovascular and metabolic work.
See the full list →Research & development
Built for the tumour that keeps coming back
Ovarian cancer spreads across the peritoneal surface rather than through a single solid mass, so carrier residence time matters as much as potency. Every programme below is designed around that.
| Code | Programme | Carrier | Stage |
|---|---|---|---|
| BGX-101 | FRα-targeted platinum prodrugPt(IV) prodrug in a folate-decorated liposome for platinum-sensitive relapse | PEGylated liposome |
Lead optimisation |
| BGX-204 | Resistance-reversal co-deliverysiRNA against efflux and repair pathways, co-loaded with a taxane | Ionisable lipid nanoparticle |
Discovery |
| BGX-310 | Peritoneal-retentive micellePARP inhibitor with a STING agonist for intraperitoneal dosing | PLGA–PEG polymeric micelle |
Discovery |
| BGX-PLAT | Organoid response platformPatient-derived organoid imaging with automated response scoring | Enabling platform |
In routine use |
How a study runs
-
STAGE 1
Scope and endpoints
We agree what the images need to prove before anything is analysed. Output is a signed statement of work naming the markers, regions, endpoints and delivery dates.
-
STAGE 2
Image QC
Every slide is checked for focus, staining consistency, tissue folds and artefacts. Anything that would distort the numbers is flagged to you and excluded or re-scanned.
-
STAGE 3
Annotation and algorithm development
Regions of interest are annotated, then a segmentation and classification approach is developed on a training subset and reviewed against your pathologist's read.
-
STAGE 4
Verification and lock
Performance is verified against ground truth. For clinical and GCP work the algorithm is then locked, so every subsequent batch is analysed identically.
-
STAGE 5
Analysis and reporting
You receive per-cell object data, summary tables, annotated image exports and a written report describing methods in enough detail to reproduce them.
Operating standards
- GCP-compliant environment
- Documented QMS
- UK GDPR
- Audit trail on every run
- Data held in the UK/EU
Send us a handful of slides.
A short feasibility pass tells you whether your endpoint is measurable before you commit a cohort to it. Most take under two weeks.